Subtopic Deep Dive

Dendrimers in Drug Delivery
Research Guide

What is Dendrimers in Drug Delivery?

Dendrimers in drug delivery use highly branched, nanoscale polymers as nanocarriers to enhance drug solubility, enable targeted therapy, and control release for improved pharmacokinetics and efficacy.

Dendrimers feature onion-like layered structures starting from a core, allowing precise surface functionalization for drug conjugation (Kannan et al., 2014, 516 citations). Key reviews cover PAMAM dendrimers for cancer therapy (Kesharwani et al., 2013, 1100 citations; Gaballu et al., 2018, 450 citations). Over 10 high-citation papers since 2012 document applications in nucleic acid and chemotherapeutic delivery, with 1366 citations for general nanoparticle systems (Wilczewska et al., 2012).

Curated Papers

Key Challenges

Why It Matters

Dendrimers address poor solubility of drugs like paclitaxel by enabling nano-formulations that avoid toxic solvents like Cremophor (Ma, 2013, 535 citations). In cancer therapy, they facilitate targeted delivery and stimuli-responsive release, reducing systemic toxicity (Hossen et al., 2018, 954 citations; Mendes et al., 2017, 675 citations). Clinical translation principles from design to applications show biocompatibility and efficacy gains (Kannan et al., 2014, 516 citations), impacting treatments for lung, ovarian, and breast cancers.

Key Research Challenges

Biocompatibility and Toxicity

Dendrimer surface charge and generation affect cytotoxicity, requiring functionalization for reduced toxicity (Kesharwani et al., 2013, 1100 citations). Balancing therapeutic loading with biocompatibility remains critical (Gaballu et al., 2018, 450 citations).

Pharmacokinetics Optimization

Dendrimers must evade clearance while achieving tumor accumulation, challenged by size and branching effects (Wilczewska et al., 2012, 1366 citations). Studies highlight needs for prolonged circulation (Mendes et al., 2017, 675 citations).

Controlled Release Mechanisms

Stimuli-responsive designs for pH or enzyme-triggered release face scalability issues (Cabane et al., 2012, 447 citations). Integrating with drugs like paclitaxel demands precise engineering (Ma, 2013, 535 citations).

Essential Papers

Nanoparticles as drug delivery systems

Agnieszka Z. Wilczewska, Katarzyna Niemirowicz, Karolina H. Markiewicz et al. · 2012 · Pharmacological Reports · 1.4K citations

Dendrimer as nanocarrier for drug delivery

Prashant Kesharwani, Keerti Jain, Nilesh Jain · 2013 · Progress in Polymer Science · 1.1K citations

Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review

Sarwar Hossen, M. Khalid Hossain, Mohammad Khairul Basher et al. · 2018 · Journal of Advanced Research · 954 citations

Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine

Domenico Lombardo, Mikhail A. Kiselev, Maria Teresa Caccamo · 2019 · Journal of Nanomaterials · 827 citations

The study of nanostructured drug delivery systems allows the development of novel platforms for the efficient transport and controlled release of drug molecules in the harsh microenvironment of dis...

Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy

Lívia P. Mendes, Jiayi Pan, Vladimir P. Torchilin · 2017 · Molecules · 675 citations

Dendrimers are highly branched polymers with easily modifiable surfaces. This makes them promising structures for functionalization and also for conjugation with drugs and DNA/RNA. Their architectu...

Metal–Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications

Yujia Sun, Liwei Zheng, Yu Yang et al. · 2020 · Nano-Micro Letters · 657 citations

Abstract Investigation of metal–organic frameworks (MOFs) for biomedical applications has attracted much attention in recent years. MOFs are regarded as a promising class of nanocarriers for drug d...

Paclitaxel Nano-Delivery Systems: A Comprehensive Review

Ping Ma · 2013 · Journal of Nanomedicine & Nanotechnology · 535 citations

Paclitaxel is one of the most effective chemotherapeutic drugs ever developed and is active against a broad range of cancers, such as lung, ovarian, and breast cancers. Due to its low water solubil...

Reading Guide

Foundational Papers

Start with Wilczewska et al. (2012, 1366 citations) for nanoparticle basics, Kesharwani et al. (2013, 1100 citations) for dendrimer-specific carriers, and Ma (2013, 535 citations) for paclitaxel case studies to build core knowledge.

Recent Advances

Study Hossen et al. (2018, 954 citations) for smart nanocarriers in cancer, Mendes et al. (2017, 675 citations) for nucleic acid delivery, and Gaballu et al. (2018, 450 citations) for PAMAM therapy advances.

Core Methods

Core techniques: PAMAM synthesis for generations G3-G5, stimuli-responsive conjugation (pH/enzyme), surface PEGylation for biocompatibility (Kannan et al., 2014; Cabane et al., 2012).

How PapersFlow Helps You Research Dendrimers in Drug Delivery

Discover & Search

Research Agent uses searchPapers and exaSearch to find dendrimer drug delivery papers like 'Dendrimer as nanocarrier for drug delivery' by Kesharwani et al. (2013), then citationGraph reveals 1100 citing works on PAMAM applications, while findSimilarPapers uncovers related stimuli-responsive systems.

Analyze & Verify

Analysis Agent applies readPaperContent to extract pharmacokinetics data from Wilczewska et al. (2012), verifies claims with CoVe against Mendes et al. (2017), and uses runPythonAnalysis for statistical comparison of citation impacts or dendrimer size distributions via NumPy/pandas, with GRADE scoring evidence strength for toxicity claims.

Synthesize & Write

Synthesis Agent detects gaps in stimuli-responsive dendrimer clinical data via gap detection, flags contradictions between early (Kannan et al., 2014) and recent reviews (Hossen et al., 2018), then Writing Agent uses latexEditText, latexSyncCitations for Kesharwani et al., and latexCompile to generate a review section with exportMermaid diagrams of dendrimer architectures.

Use Cases

"Analyze dendrimer generation effects on paclitaxel loading efficiency from Ma 2013 and similar papers"

Research Agent → searchPapers + findSimilarPapers → Analysis Agent → readPaperContent (Ma 2013) → runPythonAnalysis (extract/analyze loading stats with pandas plots) → matplotlib figure of efficiency vs. generation.

"Write a LaTeX review section on PAMAM dendrimers for cancer gene delivery citing Gaballu 2018"

Synthesis Agent → gap detection on gene delivery gaps → Writing Agent → latexEditText (draft section) → latexSyncCitations (add Gaballu 2018, Kesharwani 2013) → latexCompile → PDF with formatted citations and dendrimer diagram.

"Find open-source code for dendrimer simulation in drug release models"

Research Agent → paperExtractUrls (from Cabane 2012 stimuli-responsive papers) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs Python scripts for release kinetics simulation.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (dendrimers drug delivery) → citationGraph (top 50 citers like Wilczewska 2012) → structured report with GRADE tables on efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify toxicity claims across Hossen 2018 and Mendes 2017. Theorizer generates hypotheses on next-gen dendrimer designs from gaps in Kannan 2014 clinical principles.

Try Doxa for Dendrimers in Drug Delivery Research

Frequently Asked Questions

What defines dendrimers in drug delivery?

Dendrimers are highly branched polymers with core-shell architecture for drug encapsulation, surface modification, and controlled release (Kesharwani et al., 2013).

What are main methods for dendrimer drug conjugation?

Methods include covalent attachment, encapsulation, and electrostatic complexation, with PAMAM dendrimers common for nucleic acids and chemotherapeutics (Mendes et al., 2017; Gaballu et al., 2018).

What are key papers on dendrimers in drug delivery?

Top papers: Kesharwani et al. (2013, 1100 citations) on nanocarriers; Wilczewska et al. (2012, 1366 citations) on nanoparticles; Kannan et al. (2014, 516 citations) on clinical principles.

What open problems exist in dendrimer drug delivery?

Challenges include scaling stimuli-responsive systems, minimizing toxicity at high generations, and achieving consistent in vivo pharmacokinetics (Cabane et al., 2012; Hossen et al., 2018).